Clinical Trial Update: A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating TRC105 in combination with bevacizumab in glioblastoma completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Glioblastoma Multiforme

Drugs mentioned

• Bevacizumab (bevacizumab)
• TRC105 (carotuximab)

Snippet

Sponsor: Tracon Pharmaceuticals Inc. | Conditions: Glioblastoma, Glioblastoma Multiforme | Phase 2 | Status: COMPLETED | Results posted: 2019-06-12